Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.